Page 20 - Array Biopharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) LAS VEGAS, March 4, 2021 /PRNewswire/ -- Rare cancers account for approximately 22% of all the diagnosed cancer cases. The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100?000 per year. However, these cases are not confined to one or the other particular geography, but are disproportionately spread across the world. Many rare human cancers are not curable, and have limited number of treatment options. Rare cancers are more difficult to diagnose and are often misdiagnosed. Rarity of the cancers further complicates the running of cli...

It’s a step he tried to avoid through diet, exercise, medications, implanted devices and research into his family history, which led to the discovery that his great-grandfather died from the heart condition at 40 in 1900. Other relatives, male and female, died from it in their 30s and 40s. “I worked hard to not have to get a transplant, but there’s no escaping genetics,” Wolff said. His heart problems led him to stop performing procedures in October 2019 and start working half-time seeing only clinic patients. But with his new heart and kidney, he’s back to hiking the Ice Age Trail ...

5% Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020: Abrocitinib (PF-04965842) — In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resu...

Invesco Buys Pfizer Campus for $99M The Colorado property last changed hands in 2018, when BioMed Realty sold it to Tritower Financial Group. Jan112021 Image courtesy of Newmark Tritower Financial Group has sold 3200 Walnut, a four-building office/R&D complex totaling 151,384 square feet in Boulder, Colo. According to public records, the campus traded for $99 million. Invesco Real Estate acquired the property, which is occupied by Pfizer. The asset previously changed hands in August 2018, when BioMed Realty sold it for $52.3 million, according to CommercialEdge data. Located o...

BOULDER — Atlanta-based investment firm Invesco Ltd., through holding company 3200 Walnut Street LP, last month purchased the Boulder campus occupied by Pfizer Inc. (NYSE: PFE) for $99 million. The four-building campus centered around 3200 Walnut St. was previously owned by TFG 3200 Walnut Street Property LLC, an affiliate of Boston real estate investor Tritower Financial Group LLC. Tritower acquired the 151,384-square-foot office and lab campus in 2018 for $52.3 million, Boulder County property records show. Pfizer entered the Boulder market in 2019 with the $11 billion acquisition of Bould...